company background image
300194 logo

Fuan Pharmaceutical (Group) SZSE:300194 Stock Report

Last Price

CN¥3.92

Market Cap

CN¥4.7b

7D

9.5%

1Y

-8.6%

Updated

27 Apr, 2024

Data

Company Financials

Fuan Pharmaceutical (Group) Co., Ltd.

SZSE:300194 Stock Report

Market Cap: CN¥4.7b

300194 Stock Overview

Fuan Pharmaceutical (Group) Co., Ltd., together with its subsidiaries, research and develops, produces, and sells chemical drugs in the People's Republic of China.

300194 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance3/6
Financial Health5/6
Dividends3/6

Fuan Pharmaceutical (Group) Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Fuan Pharmaceutical (Group)
Historical stock prices
Current Share PriceCN¥3.92
52 Week HighCN¥5.15
52 Week LowCN¥2.92
Beta0.24
1 Month Change0.77%
3 Month Change0%
1 Year Change-8.62%
3 Year Change-10.30%
5 Year Change-50.44%
Change since IPO-42.83%

Recent News & Updates

Insufficient Growth At Fuan Pharmaceutical (Group) Co., Ltd. (SZSE:300194) Hampers Share Price

Apr 03
Insufficient Growth At Fuan Pharmaceutical (Group) Co., Ltd. (SZSE:300194) Hampers Share Price

Recent updates

Insufficient Growth At Fuan Pharmaceutical (Group) Co., Ltd. (SZSE:300194) Hampers Share Price

Apr 03
Insufficient Growth At Fuan Pharmaceutical (Group) Co., Ltd. (SZSE:300194) Hampers Share Price

Shareholder Returns

300194CN PharmaceuticalsCN Market
7D9.5%4.9%2.1%
1Y-8.6%-13.4%-14.2%

Return vs Industry: 300194 exceeded the CN Pharmaceuticals industry which returned -13.4% over the past year.

Return vs Market: 300194 exceeded the CN Market which returned -14.2% over the past year.

Price Volatility

Is 300194's price volatile compared to industry and market?
300194 volatility
300194 Average Weekly Movement7.4%
Pharmaceuticals Industry Average Movement7.6%
Market Average Movement8.7%
10% most volatile stocks in CN Market12.7%
10% least volatile stocks in CN Market5.2%

Stable Share Price: 300194 has not had significant price volatility in the past 3 months.

Volatility Over Time: 300194's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20043,229n/awww.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd., together with its subsidiaries, research and develops, produces, and sells chemical drugs in the People's Republic of China. It offers APIs; intermediates; and FFPs, such as anti-tumor, antibiotics and oral, as well as freeze-drying preparation for injection. The company was formerly known as Chongqing Fuan Pharmaceutical (Group) Co., Ltd.

Fuan Pharmaceutical (Group) Co., Ltd. Fundamentals Summary

How do Fuan Pharmaceutical (Group)'s earnings and revenue compare to its market cap?
300194 fundamental statistics
Market capCN¥4.66b
Earnings (TTM)CN¥268.35m
Revenue (TTM)CN¥2.77b

17.4x

P/E Ratio

1.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
300194 income statement (TTM)
RevenueCN¥2.77b
Cost of RevenueCN¥1.34b
Gross ProfitCN¥1.42b
Other ExpensesCN¥1.16b
EarningsCN¥268.35m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.23
Gross Margin51.48%
Net Profit Margin9.70%
Debt/Equity Ratio17.8%

How did 300194 perform over the long term?

See historical performance and comparison

Dividends

1.3%

Current Dividend Yield

18%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.